Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Alzheimers Dement. 2022 Jun;18(6):1128-1140. doi: 10.1002/alz.12466. Epub 2021 Sep 27.
Blood-based biomarkers of amyloid pathology and neurodegeneration are entering clinical use. It is critical to understand what factors affect the levels of these markers.
Plasma markers (Aβ42, Aβ40, NfL, T-tau, Aβ42/40 ratio) were measured on the Quanterix Simoa HD-1 analyzer for 996 Mayo Clinic Study of Aging (MCSA) participants, aged 51 to 95 years. All other data were collected during in-person MCSA visits or abstracted from the medical record.
Among cognitively unimpaired (CU) participants, all plasma markers correlated with age. Linear regression models revealed multiple relationships. For example, higher Charlson Comorbidity Index and chronic kidney disease were associated with higher levels of all biomarkers. Some relationships differed between mild cognitive impairment and dementia participants.
Multiple variables affect plasma biomarkers of amyloid pathology and neurodegeneration among CU in the general population. Incorporating this information is critical for accurate interpretation of the biomarker levels and for the development of reference ranges.
血液淀粉样蛋白病理和神经退行性变的生物标志物正开始应用于临床。了解哪些因素会影响这些标志物的水平至关重要。
对 996 名年龄在 51 至 95 岁的梅奥诊所老龄化研究（MCSA）参与者的血浆标志物（Aβ42、Aβ40、NfL、T-tau、Aβ42/40 比值）进行了 Quanterix Simoa HD-1 分析仪的检测。所有其他数据均在 MCSA 现场访问期间收集或从病历中提取。
在认知正常（CU）参与者中，所有血浆标志物均与年龄相关。线性回归模型揭示了多种关系。例如，较高的 Charlson 合并症指数和慢性肾脏病与所有生物标志物水平升高相关。轻度认知障碍和痴呆症参与者之间的一些关系存在差异。
多种变量会影响一般人群中认知正常者的血液淀粉样蛋白病理和神经退行性变的血浆生物标志物。纳入这些信息对于准确解释生物标志物水平和建立参考范围至关重要。
